Tolrestat pharmacokinetics in rat peripheral nerve

Area of Science:

• Pharmacology
• Diabetic Complications
• Neuroscience

Background:

• Diabetic polyneuropathy is a common complication of diabetes.
• Aldose reductase (AR) inhibitors are investigated for treating diabetic polyneuropathy.
• Clinical efficacy of AR inhibitors depends on their bioavailability at target sites in peripheral nerves.

Purpose of the Study:

• To investigate the relationship between tolrestat concentration and its inhibition of AR-catalyzed polyol production in rat sciatic nerves.
• To estimate the concentration of free tolrestat at the site of AR activity within the nerve.

Main Methods:

• Galactosemic rats were administered tolrestat via gavage.
• Rats were fed a galactose diet at various time points post-administration.
• Nerve galactitol levels and composite tolrestat concentrations were measured.
• In vitro studies were used to estimate free tolrestat concentration.

Main Results:

• A significant correlation was found between composite tolrestat concentration in the nerve and the reduction in nerve galactitol.
• The estimated concentration of free tolrestat at the site of AR activity was only 0.4% of the total measured nerve concentration.
• Nerve galactitol levels reflect the extent of AR inhibition by tolrestat.

Conclusions:

• The pharmacokinetics of AR inhibitors, including uptake, binding, and elimination within the nerve, are critical for their effectiveness.
• A small fraction of the total drug concentration in the nerve is available at the site of AR inhibition.
• Understanding nerve-specific pharmacokinetics is essential for developing effective AR inhibitors for diabetic polyneuropathy.